Complement Therapeutics Announces First Patient Dosed with CTx001 in the Phase I/II Opti-GAIN Study for…
Continue Reading-
First patient dosed in Gesynta Pharma’s endometriosis trial of vipoglanstat
STOCKHOLM, SWEDEN – March 11, 2026. Gesynta Pharma AB today announced that the first patient…
Continue Reading -
Neuro Event Labs Receives FDA 510(k) Clearance for the Nelli® Seizure Monitoring System
Tampere, Finland — 24th November 2025 Neuro Event Labs Oy (NEL), a global healthcare diagnostics…
Continue Reading -
Step Pharma announces completion of €38 million Series C financing
Step Pharma announces completion of €38 million Series C financing • Financing will support the…
Continue Reading -
Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD
Complement Therapeutics Receives FDA IND Clearance...
Continue Reading -
Ribbon Bio and Scala Biodesign into Powerful Partnership Focused on Customers
In Powerful Partnership Focused on Customers, Ribbon Bio and Scala Biodesign Advance Enzyme Innovation with…
Continue Reading -
ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines
ARTHEx Biotech Upsizes Series B Financing Round to $87M...
Continue Reading -
Gesynta Pharma Announces Second Closing of Series B Now Totaling SEK 347m – HealthCap and Hadean Growth Fund Join Strong Investor Syndicate
STOCKHOLM, SWEDEN – July 22, 2025. Gesynta Pharma AB today announced it has raised an…
Continue Reading -
SAGA Diagnostics® Announces Medicare Coverage for Pathlight™ MRD Test in Breast Cancer Across All Subtypes
Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer…
Continue Reading
